Inhibition of baloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance

Hypertension Research

Volumn 30, Issue 10, 2007, Pages 971-978

  Chen, Ming ^a,b   Ichiki, Toshihiro ^a   Ohtsubo, Hideki ^a   Imayama, Ikuyo ^a   Inanaga, Keita ^a   Miyazaki, Ryouhei ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Balloon injury; Insulin resistance; Neointimal formation; Olmesartan; Pravastatin

Indexed keywords

INSULIN; KI 67 ANTIGEN; OLMESARTAN; PRAVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; FRUCTOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; BLOOD PRESSURE; CAROTID ARTERY INJURY; CELL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MONOTHERAPY; MORPHOMETRICS; NICK END LABELING; NONHUMAN; RAT; ANIMAL; CAROTID ARTERY DISEASE; CELL PROLIFERATION; COMMON CAROTID ARTERY; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STEM CELL;

ANGIOPLASTY, BALLOON; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; CAROTID ARTERY DISEASES; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELL COUNT; CELL PROLIFERATION; FRUCTOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; STEM CELLS; TETRAZOLES;

EID: 36248930870     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.971     Document Type: Article

References (37)

1. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
2. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-1100.
3. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778.
4. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
5. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
6. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
7. Barnett AH, Bain SC, Bouter P, et al: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
8. Dahlof B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
9. Wilt TJ, Bloomfield HE, MacDonald R, et al: Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164: 1427-1436.
10. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987.
11. Horiuchi M, Cui TX, Li Z, et al: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-112.
12. Li Z, Iwai M, Wu L, et al: Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44: 758-763.
13. Nishikawa H, Miura S, Shimomura H, et al: Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis. J Cardiol 2005; 45: 107-113.
14. Morawietz H, Erbs S, Holtz J, et al: Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006; 114: I296-I301.
15. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K: Effect of TNF-alpha-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 2002; 39: 578-580.
16. Kim S, Izumi Y, Izumiya Y, Zhan Y, Taniguchi M, Iwao H: Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol 2002; 22: 1299-1304.
17. Li C, Yang CW, Park JH, et al: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004; 286: F46-F57.
18. Tokunou T, Shibata R, Kai H, et al: Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation 2003; 108: 1246-1252.
19. Simper D, Wang S, Deb A, et al: Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation 2003; 108: 143-149.
20. D'Angelo G, Elmarakby AA, Pollock DM, Stepp DW: Fructose feeding increases insulin resistance but not blood pressure in Sprague-Dawley rats. Hypertension 2005; 46: 806-811.
21. Okada K, Hirano T, Ran J, Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats. Hypertens Res 2004; 27: 293-299.
22. Yamakawa T, Tanaka S, Numaguchi K, et al: Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000; 35: 313-318.
23. Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A: Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem 2002; 277: 6214-6222.
24. Martin G, Duez H, Blanquart C, et al: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-1432.
25. Morikawa-Futamatsu K, Adachi S, Maejima Y, et al: HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci 2006; 79: 1380-1390.
26. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-268.
27. Wiss RH, Ramirez A, Joo A: Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J Am Soc Nephrol 1999; 10: 1880-1890.
28. Walter DH, Rittig K, Bahimann FH, et al: Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
29. Yamamoto E, Yamashita T, Tanaka T, et al: Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 2007; 27: 556-563.
30. Tanaka K, Sata M, Hirata Y, Nagai R: Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93: 783-790.
31. Strehlow K, Werner N, Berweiler J, et al: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003; 107: 3059-3065.
32. Trovati M, Anfossi G: Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35-40.
33. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y: Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 2001; 186: 1-10.
34. Hsueh WA, Law RE: Insulin signaling in the arterial wall. Am J Cardiol 1999; 84: 21J-24J.
35. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
36. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C: Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003; 93: 406-413.
37. Bloomgarden ZT: Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care 2005; 28: 2312-2319.